Heme cascade-triggered nanovesicles for myocardial ischemic core delivery

Read full text Summarise with VIRAT
Authors: Hui Chen, Ying Yang, Mirenuer Aikebaier, Hao Wang, Li Zheng, Yifeng Zhang, Qing Zha, Shuyao Shan, Yanping Wang, Jiawei Chen, Fanyi Huang, Yiping Li
+5 more Yunkai Tang, Yawei Du, Wenguo Cui, Ke Yang, Yan Liu
Cited by: 0
References: 53

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Myocardial ischemia-reperfusion injury (MIRI) remains a significant therapeutic challenge due to insufficient targeted drug delivery. Recognizing heme as a key endogenous signal that has yet to be utilized in delivery systems, we designed the first heme-responsive nanovesicle (DecAS-PC@NM) for lesion-specific therapy through a cascade reaction involving two functionalized phospholipids. Specifically, heme activates the artemisinin-modified phospholipid (A-PC) to generate reactive oxygen species, which oxidize the thioether structure in another phospholipid (S-PC), triggering a hydrophilic-to-hydrophobic transition and subsequent vesicle disassembly. Co-assembly with neutrophil membranes further enhances chemotaxis toward inflammatory sites. In vitro studies confirm the unique heme responsiveness of DecAS-PC@NM, while in vivo data highlight its ischemic core targeting and significant therapeutic improvement. This innovative heme-triggered phospholipid cascade offers a promising strategy for MIRI treatment. • Heme as a specific trigger for the ischemic core. • Heme-cascade response based on phospholipids. • Heme cascade-triggered vesicles for MIRI treatment.

Fields of Study & Subjects

Nanoparticle-Based Drug Delivery Nanoplatforms for cancer theranostics Extracellular vesicles in disease

Publication details

Journal / source
Bioactive Materials
Volume
62
Pages
655–668
Publication date
21 March 2026
Language
EN